I (re)joined Genentech in 2010 to work on biomarkers in oncology. It was becoming clear that diagnostic markers of disease biology were critical for developing targeted therapeutics. Genentech was on the forefront of these scientific endeavours and was and continues to put significant effort and resources for research to identify predictive biomarkers.
This was a return for me having previously worked as a post-doctoral fellow at Genentech years earlier. It was no surprise when I returned to the same cooperative, creative and highly driven scientific expertise that I had already witnessed.
Mol Cancer Ther. 2013 Jun;12(6):1122-30.
My group focuses on identifying prognostic and predictive biomarkers to support clinical trials. We focus on the preclinical validation of prospective biomarkers to confirm mechanism of action and subsequently incorporate sophisticated technologies that enable measurement in clinical specimens.
We have worked on multiple studies supporting clinical trials in solid tumors but more recently we are now focused on hematologic malignancies. Currently we are working to identify relevant and measureable biomarkers across clinical trials evaluating treatment options in Non-Hodgkins lymphoma (NHL). NHL is a heterogeneous disease and novel biomarker strategies will be key for rational personalized treatment options for patients.